Submission Details
| 510(k) Number | K182276 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | August 22, 2018 |
| Decision Date | November 01, 2018 |
| Days to Decision | 71 days |
| Submission Type | Special |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
K182276 is an FDA 510(k) clearance for the MEDRAD MRXperion MR Injection System and MR Injection System Syringe Kit, a Injector And Syringe, Angiographic (Class II — Special Controls, product code DXT), submitted by Bayer Medical Care, Inc. (Indianola, US). The FDA issued a Cleared decision on November 1, 2018, 71 days after receiving the submission on August 22, 2018. This device falls under the Cardiovascular review panel. Regulated under 21 CFR 870.1650.
| 510(k) Number | K182276 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | August 22, 2018 |
| Decision Date | November 01, 2018 |
| Days to Decision | 71 days |
| Submission Type | Special |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
| Product Code | DXT — Injector And Syringe, Angiographic |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 870.1650 |